Consistently with the results described above, treatment with hybrid exosomes from NAFLD patients loaded with OA decreased phospho-RIP-1 expression in the nuclei, as well as treatment with hybrid exosomes from healthy subjects loaded with PA increased phospho-RIP-1 in the nuclei (Fig. 5). The gene discussed is RIPK1; the disease is metabolic dysfunction-associated steatotic liver disease.